Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC).

Alberto F. Sobrero(Ospedale Policlinico San Martino), Roger Sidhu(Amgen (United States)), Florian Lordick(Leipzig University), Timothy Price(Basil Hetzel Institute), Thierry André(Inserm), Marc Peeters(University of Antwerp), Andrés Cervantes(INCLIVA Health Research Institute), Ying Tian(Amgen (United States)), Emily Chan(Ghent University Hospital), Michel Ducreux(Université Paris-Saclay), Yevhen Hotko(Ghent University Hospital)
Journal of Clinical Oncology
May 20, 2012
10.1200/jco.2012.30.15_suppl.3535
Cited by 5

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k